Skip to NavigationSkip to content

Doctors of the World

The Pharmafocus debate: Is the price of new hepatitis C treatments fair?

Published on 27/04/15 at 01:26pm

YES - says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that blaming the pharma patent system for hepatitis C drugs’ prices is a non-starter.

New hepatitis C treatments have been a regular feature in healthcare news of late, not least because they offer that most elusive of gifts: a cure.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches